Gelatin has demonstrated great utility and versatility in many advanced drug delivery systems, including targeted drug delivery or localized drug delivery systems. Examples include large and small molecules (biologics) encapsulated in micro- and nano-spheres, gel films, ocular inserts, and eye drops. In all of these applications, gelatin offers great flexibility in the control of drug release across a wide range of chemistries (hydrophobic, hydrophilic, or neutral). Drugs that have struggled from poor bio-availability have been successfully formulated with gelatin (Nikkhah, et al., 2016).
Controlling drug delivery: Gelatin microspheres can be used in spatio-temporal control strategies, enabling for example sustained release of drugs. The use of low endotoxin gelatin helps minimize the risk of endotoxin-induced immune response.
Gelatin-based micro and submicron particles: a growing use in the field of biomolecule- and drug delivery and regenerative medicine
Recently, gelatin based micro- and submicron particles, have gained interest in the field of biomolecule- and drug delivery and regenerative medicine1-2. Endotoxins are important for these applications. Any remaining endotoxin may cause significant adverse immunogenic effects. X-Pure is ultrapure, low in endotoxin and without compromise in the unique tunable and biocompatible characteristics of natural gelatin. With X-Pure, it is now possible to prepare gelatin micro/submicron particles and colloidal injectable gels complying with the highest regulation and quality standards for biomolecule- and drug delivery and regenerative medicine.
1. Young S. et al. 2005. Gelatin as a delivery vehicle for the controlled release of bioactive molecules. Journal of controlled release: official journal of the Controlled Release Society 2005, 109 (1-3), 256-74.
2. Elzoghby A. O. 2013. Gelatin-based nanoparticles as drug and gene delivery systems: reviewing three decades of research. Journal of controlled release: official journal of the Controlled Release Society 2013, 172 (3), 1075-91.